Eli Lilly and Company raised earnings guidance for the year 2024. For the year, the company expects revenue of $42.4 billion to $43.6 billion against previous guidance of $40.4 billion to $41.6 billion. Earnings per Share (reported) of $13.05 to $13.55 against previous guidance of $11.80 to $12.30.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
805.1 USD | +2.79% | +5.22% | +37.90% |
06:00pm | Global markets live: Microsoft, Roche, BMW, Nintendo, Nordson... | |
04:48pm | Eli Lilly: conclusive trial in Crohn's disease | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.90% | 705B | |
+32.82% | 583B | |
-3.67% | 364B | |
+19.70% | 332B | |
+5.21% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+9.21% | 169B | |
-0.92% | 162B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly and Company Raises Earnings Guidance for the Year 2024